Bellicum Pharmaceuticals (NASDAQ:BLCM) was upgraded by investment analysts at Wells Fargo from a “market perform” rating to an “outperform” rating in a research report issued on Wednesday. The firm presently has a $6.85 price objective on the biopharmaceutical company’s stock, down from their prior price objective of $8.30. Wells Fargo’s price target points to a potential downside of 16.97% from the company’s previous close.
A number of other research analysts have also issued reports on BLCM. Raymond James Financial reiterated a “buy” rating on shares of Bellicum Pharmaceuticals in a report on Tuesday, December 12th. ValuEngine upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Wednesday, January 3rd. BidaskClub upgraded Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Thursday, January 4th. Zacks Investment Research upgraded Bellicum Pharmaceuticals from a “hold” rating to a “buy” rating and set a $10.00 target price for the company in a report on Wednesday, January 10th. Finally, Cantor Fitzgerald restated an “overweight” rating and issued a $10.00 price target (down from $12.00) on shares of Bellicum Pharmaceuticals in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $17.88.
NASDAQ:BLCM opened at $8.25 on Wednesday. The firm has a market capitalization of $226.61, a P/E ratio of -2.41 and a beta of 0.47. Bellicum Pharmaceuticals has a 12-month low of $5.02 and a 12-month high of $14.49. The company has a quick ratio of 8.37, a current ratio of 8.37 and a debt-to-equity ratio of 0.41.
In other Bellicum Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker sold 260,600 shares of the firm’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $8.63, for a total value of $2,248,978.00. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 18.77% of the stock is owned by company insiders.
A number of institutional investors have recently bought and sold shares of BLCM. MYDA Advisors LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the fourth quarter worth about $118,000. LPL Financial LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the fourth quarter worth about $140,000. Cubist Systematic Strategies LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the third quarter worth about $164,000. Ellington Management Group LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the fourth quarter worth about $222,000. Finally, Virtus Fund Advisers LLC acquired a new stake in shares of Bellicum Pharmaceuticals during the fourth quarter worth about $343,000. Institutional investors own 54.57% of the company’s stock.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on discovering and developing novel cellular immunotherapies for the treatment of hematological cancers, solid tumors, and orphan inherited blood disorders in the United States and internationally. The company's clinical product candidates include BPX-501, an adjunct T cell therapy in multiple Phase I/II clinical trials, administered after allogeneic hematopoietic stem cell transplantation; and BPX-601, a GoCAR-T product candidate in Phase I clinical trial for treating solid tumors expressing the prostate stem cell antigen.
Receive News & Ratings for Bellicum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.